The Center for Medicare and Medicaid Innovation ("CMMI") is set to reshape value-based care. In the third of a three-part series highlighting this new direction, this summary is focused on CMMI's efforts regarding drugs,...more
6/13/2025
/ Centers for Medicare & Medicaid Services (CMS) ,
CMMI ,
Data Collection ,
Data Management ,
Digital Health ,
Drug Pricing ,
Health Insurance ,
Healthcare ,
Healthcare Reform ,
Life Sciences ,
Medicaid ,
Medical Devices ,
Medicare ,
Patient Access ,
Pharmaceutical Industry ,
Value-Based Care
The U.S. Department of Justice Antitrust Division ("DOJ") recently resolved a criminal case with Teva Pharmaceuticals and Glenmark Pharmaceuticals via deferred prosecution agreements ("DPAs"), which include a novel remedy for...more
9/5/2023
/ Anti-Competitive ,
Antitrust Violations ,
Bid Rigging ,
Competition ,
Corporate Counsel ,
Criminal Antitrust Litigation ,
Criminal Conspiracy ,
Criminal Investigations ,
Criminal Prosecution ,
Deferred Prosecution Agreements ,
Department of Justice (DOJ) ,
Divestiture ,
Enforcement Actions ,
Generic Drugs ,
Health Care Providers ,
Healthcare ,
Indictments ,
Life Sciences ,
Pharmaceutical Industry ,
Popular ,
Price-Fixing ,
Teva Pharmaceuticals
The Senate Judiciary Committee is showing renewed Congressional interest in oversight of the pharmaceutical industry, with five bipartisan drug bills on the agenda for review and discussion on February 9, 2023....more
Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar companies that relate to the...more
10/19/2018
/ Antitrust Division ,
Disclosure Requirements ,
Federal Trade Commission (FTC) ,
Hatch-Waxman ,
Life Sciences ,
Manufacturers ,
Medicare Prescription Drug Improvement and Modernization Act (MMA) ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs